Research Article
No access
Published Online: 25 March 2008

Adverse Effects of Transdermal Opiates Treating Moderate-Severe Cancer Pain in Comparison to Long-Acting Morphine: A Meta-Analysis and Systematic Review of the Literature

Publication: Journal of Palliative Medicine
Volume 11, Issue Number 3

ABSTRACT

Background: To assess the adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison with slow release oral morphine.
Methods: A systematic review of the literature in the MEDLINE and EMBASE databases from 1966 to June 2007 was independently performed by two authors. All phase 3 randomized trials comparing transdermal opiates and slow-release oral morphine in the treatment of moderate–severe cancer pain were considered eligible and included in the analysis. The primary end point was the overall adverse effects odds ratio (OR); secondary end points were the overall gastrointestinal adverse effects, constipation, nausea, somnolence, patients' preference, and trial withdrawal. Heterogeneity was analyzed using the Mantel-Haenszel test, and outcome analysis was performed using a random effect model; an α error lower than 5% was assumed as statistically significant.
Results: Four trials met the selection criteria. The safety of transdermal opiates (fentanyl and buprenorphine) and slow-release oral morphine was analyzed in 425 patients. A significant difference in favor of transdermal opiates was observed for constipation (OR = 0.38, p < 0.001), and patients' preference (OR = 0.43, p = 0.014, in the three trials investigating transdermal fentanyl). No significant differences were observed for overall adverse effects, overall gastrointestinal adverse effects, overall neurologic adverse effects, nausea, somnolence, hypoventilation, trial withdrawal, and changes in opiate treatments.
Conclusion: Although no difference in the overall adverse effect profile exists between transdermal opiates and slow release oral morphine, the difference in some adverse effects (mainly constipation) seems to favor transdermal opiates in the preference of patients with moderate-severe cancer pain.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

cover image Journal of Palliative Medicine
Journal of Palliative Medicine
Volume 11Issue Number 3April 2008
Pages: 492 - 501
PubMed: 18363493

History

Published in print: April 2008
Published online: 25 March 2008

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Davide Tassinari
Department of Oncology, Supportive and Palliatice Care Unit, City Hospital, Rimini, Italy.
Sergio Sartori
Department of Internal Medicine, Ferrara, Italy.
Emiliano Tamburini
Department of Oncology, Supportive and Palliatice Care Unit, City Hospital, Rimini, Italy.
Emanuela Scarpi
Palliative Care Unit, Forlì, Italy.
William Raffaeli
Department of Hospice and Palliative Care Service, Infermi Hospital, Rimini, Italy.
Paola Tombesi
Department of Internal Medicine, Ferrara, Italy.
Marco Maltoni
Palliative Care Unit, Forlì, Italy.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top